The UK and US have established a landmark trade agreement that will ensure zero import taxes on British drug products being sold in the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the NHS. This pledge secures that duties on these vital products will stay at zero for a period of the next three years.
This deal comes after earlier statements to significantly raise import taxes on patented drug products, with increases mentioned up to 100%.
"This deal between the United Kingdom bolsters the worldwide climate for innovative medicines and brings much-needed equity to transatlantic drug exports," an announcement noted.
Trade Impact
Pharmaceuticals represent one of the the United Kingdom's most significant export categories to the US, which is clearly the largest market for large British pharmaceutical firms.
Export figures show that in the 12 months prior to last September, the UK shipped medicines valued at £11.1bn to the US. This value represented a significant portion of British export trade in that span.
"This guarantee secures jobs, boosts investment and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.
Specific British Pledges
The agreement entails several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. In the past, refunds topped 20%.
Recent Tensions
The pact follows a protracted row between the sector and the ministers over drug pricing and regulatory access.
This friction were exacerbated by assertions that US consumers were charged significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been halted or scrapped, while major investments have been pledged toward American operations.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had shrunk as a share of its total funding over the last ten years.
